Estudo mestre de triagem para determinar a situação do biomarcador e a elegibilidade potencial do estudo para pacientes com tumores malignos
Screening Study for Participants With Malignant Tumors
- Câncer
- Tumores Sólidos
Recrutando
- Bahia
- Ceará
- Minas Gerais
- Rio de Janeiro
- Rio Grande do Sul
- Santa Catarina
- São Paulo
NCT05419375 BX43361
Resumo do Estudo
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Critérios de elegibilidade
General Inclusion Criteria:
- Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
- Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial
Inclusion Criteria for Participants with Stage III NSCLC
- Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
General Exclusion Criteria:
- History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
- Any condition that may affect the interpretation of study results
- Significant liver or cardiovascular disease
- Prior allogenic stem-cell or solid-organ transplantation
For the latest version of this information please go to www.forpatients.roche.com